Recent reports show resistance to receptor tyrosine kinase (RTK) inhibitors is correlated to EGFR lipid raft localization in breast cancer cells, and that disrupting lipid rafts by cholesterol depletion sensitizes these resistant breast cancer cells to EGFR inhibitors, dampening Akt activation [29]. The gene discussed is AKT1; the disease is breast cancer.